Miniatura

Fitxers

ciab552.pdf (7.08 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-06-16

Llicència de publicació

cc by-nc-nd (c) Douglas, Pamela S. et al., 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/182347

Cardiovascular Risk and Health Among People With HIV Eligible for Primary Prevention: Insights From the REPRIEVE Trial

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1093/cid/ciab552

Resum

Background: In addition to traditional cardiovascular (CV) risk factors, antiretroviral therapy, lifestyle, and human immunodeficiency virus (HIV)-related factors may contribute to future CV events in persons with HIV (PWH). Methods: Among participants in the global REPRIEVE randomized trial, we characterized demographics and HIV characteristics relative to ACC/AHA pooled cohort equations (PCE) for atherosclerotic CV disease predicted risk and CV health evaluated by Life's Simple 7 (LS7; includes smoking, diet, physical activity, body mass index, blood pressure, total cholesterol, and glucose). Results: Among 7382 REPRIEVE participants (31% women, 45% Black), the median PCE risk score was 4.5% (lower and upper quartiles Q1, Q3: 2.2, 7.2); 29% had a PCE score <2.5%, and 9% scored above 10%. PCE score was related closely to known CV risk factors and modestly (<1% difference in risk score) to immune function and HIV parameters. The median LS7 score was 9 (Q1, Q3: 7, 10) of a possible 14. Only 24 participants (0.3%) had 7/7 ideal components, and 36% had ≤2 ideal components; 90% had <5 ideal components. The distribution of LS7 did not vary by age or natal sex, although ideal health was more common in low sociodemographic index countries and among Asians. Poor dietary and physical activity patterns on LS7 were seen across all PCE scores, including the lowest risk categories. Conclusions: Poor CV health by LS7 was common among REPRIEVE participants, regardless of PCE. This suggests a critical and independent role for lifestyle interventions in conjunction with conventional treatment to improve CV outcomes in PWH. Clinical Trials Registration: NCT02344290. AIDS Clinical Trials Group study number: A5332.

Matèries

VIH (Virus), Malalts de sida, Factors de risc en les malalties, Estils de vida, Malalties cardiovasculars

Matèries (anglès)

HIV (Viruses), AIDS patients, Risk factors in diseases, Lifestyles, Cardiovascular diseases

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

DOUGLAS, Pamela s., UMBLEJA, Triin, BLOOMFIELD, Gerald s., FICHTENBAUM, Carl j., ZANNI, Markella v., OVERTON, Edgar t., FITCH, Kathleen v., KILEEL, Emma m., ABERG, Judith a., CURRIER, Judith, SPONSELLER, Craig a., MELBOURNE, Kathleen, AVIHINGSANON, Anchalee, BUSTORFF, Flavio, ESTRADA, Vicente, RUXRUNGTHAM, Kiat, SAUMOY, Maria, NAVAR, Ann marie, HOFFMANN, Udo, RIBAUDO, Heather j., GRINSPOON, Steven, REPRIEVE investigators. Cardiovascular Risk and Health Among People With HIV Eligible for Primary Prevention: Insights From the REPRIEVE Trial. _Clinical Infectious Diseases_. 2021. Vol. 73, núm. 11, pàgs. 2009-2022. [consulta: 25 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/182347]

Exportar metadades

JSON - METS

Compartir registre